
John G. Rizk, RPh, MSc.1,* Jose G. Lazo Jr., PharmD2,* Aashish Gupta, MD3 Carl J. Lavie, MD3 Mark B. Effron, MD3

1 Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland
2 Department of Pharmacy, UCSF Medical Center, University of California San Francisco, California
3 Department of Cardiology, John Ochsner Heart and Vascular Institute, Ochsner Clinical School—The University of Queensland School of Medicine, New Orleans, Louisiana

Address for correspondence John G. Rizk, RPh, MSc, Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, 220 Arch Street, 12th Floor, Room 01-409-E, MD 21201 (e-mail: john.rizk@umaryland.edu).

In December 2021, the U.S. Food and Drug Administration (FDA) issued emergency use authorizations (EUAs) for two oral antiviral at-home treatments for coronavirus disease 2019 (COVID-19), nirmatrelvir/ritonavir (Paxlovid [Pfizer]), and molnupiravir (Merck).

While their mechanisms of action somewhat differ, these agents are considered “game-changers” by some observers, since they do not require administration by intravenous infusion as monoclonal antibodies do. Initial efficacy studies suggest that nirmatrelvir/ritonavir may be more effective than molnupiravir, but it also has more drug interactions of potential concern, especially related to anticoagulant therapy. Molnupiravir does not have any reported interaction with anticoagulant agents. Additionally, remdesivir (Veklury [Gilead]) and bebtelovimab (Lilly) are parenteral agents recently granted an EUA for use in the outpatient setting as treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, who are at high risk for progression to severe COVID-19, including hospitalization or death.

Neither of these agents have any known interaction with anticoagulants.

Nirmatrelvir/ritonavir is comprised of nirmatrelvir, a SARS-CoV-2 main protease inhibitor, co-packaged with ritonavir, a protease inhibitor. While ritonavir has no activity against SARS-CoV-2, its inhibition of CYP3A-mediated metabolism of nirmatrelvir increases nirmatrelvir plasma concentrations to levels anticipated to inhibit SARS-CoV-2 replication. Outpatient nirmatrelvir/ritonavir use is authorized for treatment of mild to moderate COVID-19 disease in adults and pediatric patients older than 12 and weighing more than 40 kg who are at high risk for severe progression of COVID-19.

Regarding pharmacokinetics, nirmatrelvir is primarily eliminated by the kidneys, with minimal liver metabolism. However, ritonavir is known to be an inhibitor of cytochrome P450 (CYP) isoenzymes, particularly a strong CYP3A4 and weak 2D6 inhibitor, and an inhibitor of P-glycoprotein (P-gp).

Additionally, ritonavir is an inducer of CYP 1A2, 2B6, 2C19, and 2C9. On that premise, the risk of drug interactions with nirmatrelvir/ritonavir and many commonly used medications, including statins and antiarrhythmic drugs, may preclude its use or need careful adjustment of dosing. Additionally, the FDA label flags two anticoagulants for nirmatrelvir/ritonavir users, rivaroxaban and warfarin, while other direct oral anticoagulants (DOACs) are not mentioned. Inhibition of CYP3A4 and P-gp leads to increased plasma levels and pharmacodynamic effects of rivaroxaban, thus potentially increasing bleeding risk (area under the curve [AUC] change 153%, maximum concentration (Cmax) change 53%).

Antiplatelet or anticoagulant therapy is not currently recommended for outpatients with COVID-19, the largest population of individuals infected. The ACTIV-4B
Outpatient Thrombosis Prevention Trial,\textsuperscript{10} aimed at evaluating antithrombotic therapy in outpatients with COVID-19, was a randomized, adaptive, double-blind, placebo-controlled trial that randomly assigned outpatients with COVID-19 in a 1:1:1:1 ratio to receive aspirin (81 mg orally once daily), prophylactic-dose apixaban (2.5 mg orally twice daily), therapeutic-dose apixaban (5 mg orally twice daily), or matching placebo for 45 days. Treatment with aspirin or apixaban compared with placebo did not reduce the rate of composite clinical outcomes, with risk of adjudicated primary composite outcome with placebo being 0.0% (95% CI, 0.0–2.8%), with aspirin 0.0% (95% CI, 0.0–2.6%), 0.7% in the prophylactic apixaban group (95% CI, 0.1–4.1%) and 1.4% in the therapeutic apixaban group (95% CI, 0.4%–5.0%), respectively. In addition, a phase 2b placebo controlled randomized study of rivaroxaban 10 mg daily in patients with COVID-19 not currently hospitalized or under immediate consideration for hospitalization was terminated, after almost 500 of the target 600 participants were enrolled because a prespecified interim analysis of the first 200 participants in the intent-to-treat population demonstrated it would be futile to attempt to show a beneficial effect of rivaroxaban in this patient population. Disease progression rate with rivaroxaban was 20.7 versus 19.8% in placebo groups, with non-significant risk difference of –1.0 (95% confidence interval, –6.4 to 8.4%; \( p = 0.78 \)). Thus, at this time, routine anticoagulation is not recommended for patients with COVID-19 who do not need hospitalization.

Despite these findings, patients at high risk of thrombosis are usually prescribed long-term anticoagulation therapy. Moreover, COVID-19 patients who require anticoagulants for atrial fibrillation or flutter, recent surgery or immobility, heart valve replacement, ischemic stroke or other thrombotic event should be treated with oral anticoagulant (OAC) therapy. This may be a problem if they develop mild to moderate COVID-19 and are considered high risk for severe COVID-19 disease as they would then be candidates for nirmatrelvir/ritonavir.

While the package insert for nirmatrelvir/ritonavir mentions an increased bleeding risk with rivaroxaban and warns against concomitant use, it is may be reasonable to adjust the dose of apixaban, which like rivaroxaban is a substrate of both CYP3A4 and P-gp. Apixaban, edoxaban, and dabigatran have dose reduction strategies in their prescribing information for certain high bleeding risk populations that can be adopted for use with nirmatrelvir/ritonavir. For apixaban, it may be considered to reduce the dose to 2.5 mg twice daily, and in patients already taking apixaban at a dose of 2.5 mg daily, concurrent use of nirmatrelvir/ritonavir should be avoided.\textsuperscript{12} For edoxaban, one might consider reducing the dose to 30 mg once daily.\textsuperscript{13} Similarly, consideration of dose reduction of dabigatran to 110 mg twice daily instead of the standard dose of 150 mg twice daily\textsuperscript{14} may allow for dabigatran use with nirmatrelvir/ritonavir. However, unlike rivaroxaban, there are no data available evaluating or demonstrating the same level of protection from thrombotic events, or less bleeding, if reduced dose strategies are used in combination with nirmatrelvir/ritonavir. There are no reported drug interactions with the use of low molecular weight heparin (LMWH) (e.g., enoxaparin), unfractionated heparin (UFH), fondaparinux, or the antiplatelet agent aspirin, with nirmatrelvir/ritonavir, and these agents can be considered better alternatives if nirmatrelvir/ritonavir is used.

**Fig. 1** Proposed algorithm for the management of oral anticoagulation therapy in COVID-19 outpatients prescribed nirmatrelvir/ritonavir. COVID-19, coronavirus disease 2019; DOAC, direct oral anticoagulant; INR, international normalized ratio; LMWH, low molecular weight heparin; OAC, oral anticoagulant.
Warfarin, which is metabolized by CYP450 isozymes including CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4, also interacts with nirmatrelvir/ritonavir.\(^\text{5}\) The S-enantiomer, which is the more potent isomer, is metabolized by CYP2C9, while the R-enantiomer is metabolized by CYP1A2 and 3A4.\(^\text{15}\) Induction of CYP1A2 and CYP2C9 leads to decreased levels of R-warfarin while minimal pharmacokinetic effect is noted on S-warfarin when co-administered with ritonavir. Decreased R-warfarin levels may lead to reduced anticoagulation, therefore it is recommended that international normalized ratio (INR) is closely monitored when warfarin is administered with ritonavir.

When selecting an agent for thromboprophylaxis in COVID-19 outpatients who are already on an anticoagulant or are at high risk for arterial or venous thromboembolism (VTE), it is essential to conduct a thorough review of potential drug interactions which may diminish efficacy or increase risk of bleeding. Many of the drug interactions are manageable and should not preclude patients from taking nirmatrelvir/ritonavir. Nirmatrelvir/ritonavir is only for outpatient use prior to hospitalization for COVID-19 and the current data and recommendations are against initiating patient use prior to hospitalization for COVID-19 outpatients who are already on an anticoagulant (VTE), it is essential to conduct a thorough review of potential drug interactions which may diminish efficacy or increase risk of bleeding. Many of the drug interactions are manageable and should not preclude patients from taking nirmatrelvir/ritonavir. If a patient is on another DOAC (e.g., apixaban, dabigatran, edoxaban), consider using lower doses of these drugs; however, there is no data available on safety or efficacy of lower doses of alternative DOACs in combination with nirmatrelvir/ritonavir. If there is concern about temporarily stopping OAC, bridging with LMWH, or using lower doses of OAC, patients can be placed on other oral antivirals (molnupiravir), intravenous antivirals (remdesivir), or a monoclonal antibody (bebtelovimab)\(^\text{3}\) instead of using nirmatrelvir/ritonavir (►Fig. 1) and continued on their current OAC at therapeutic doses.

Authors’ Contributions
J.R. and J.G.L. contributed toward conceptualization. All the authors contributed toward data curation, writing, reviewing, and editing.

Funding
None.

Conflict of Interest
M.B.E. has equity in and receives a pension from Eli Lilly and Company. The remaining authors do not have any conflict of interest.

References

